U.S. Capital Wealth Advisors’s Summit Therapeutics SMMT Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$228K	Buy	12,009 +9	+0.1%	+$146	0.01%	906
2025 Q4	$210K	Hold	12,000	–	–	0.01%	913
2025 Q3	$248K	Sell	12,000 -25	-0.2%	-$606	0.01%	827
2025 Q2	$256K	Hold	12,025	–	–	0.01%	768
2025 Q1	$232K	Buy	+12,025	New	+$241K	0.01%	767

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

U.S. Capital Wealth Advisors's SMMT Position: Q1 2026 in Review

U.S. Capital Wealth Advisors increased its Summit Therapeutics (SMMT) stake by 0.08% in Q1 2026, buying an estimated $146 and bringing the position to 12,009 shares worth $228K. The position accounts for 0.01% of the portfolio, ranked #906.

U.S. Capital Wealth Advisors first reported a position in SMMT in Q1 2025 and has held it in 5 quarters since. The position peaked at $256K in Q2 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

U.S. Capital Wealth Advisors held 12,009 shares of Summit Therapeutics worth $228K as of Q1 2026.
U.S. Capital Wealth Advisors bought 9 Summit Therapeutics shares in Q1 2026, an estimated $146.
Summit Therapeutics made up 0.01% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #906 holding.
U.S. Capital Wealth Advisors first reported a position in Summit Therapeutics in Q1 2025 and has held it in 5 quarters since.
U.S. Capital Wealth Advisors's Summit Therapeutics position peaked at $256K in Q2 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.